Skip to main content

Hyperfine, Inc. (HYPR) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $1.84 (+10.84%)

Consensus Target
$1.60
Upside
-13.0%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $1.60High $1.60

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Mar 22, 2024Larry BiegelsenWells Fargo$1.60-13.0%
Aug 11, 2022Larry BiegelsenWells Fargo$2.40+30.4%

HYPR vs Sector & Market

MetricHYPRHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1818
Target Upside-13.0%+1150.3%+14.9%
P/E Ratio-3.446.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$20M$20M$20M1
2027-12-31$26M$26M$26M1
2028-12-31$24M$24M$24M1
2029-12-31$29M$29M$29M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.35$-0.34$-0.341
2027-12-31$-0.33$-0.33$-0.331
2028-12-31$-0.34$-0.34$-0.341
2029-12-31$-0.29$-0.29$-0.291

Frequently Asked Questions

What is the analyst consensus for HYPR?

The consensus among 1 analysts covering Hyperfine, Inc. (HYPR) is Buy with an average price target of $1.60.

What is the highest price target for HYPR?

The highest price target for HYPR is $2.40, set by Larry Biegelsen at Wells Fargo on 2022-08-11.

What is the lowest price target for HYPR?

The lowest price target for HYPR is $1.60, set by Larry Biegelsen at Wells Fargo on 2024-03-22.

How many analysts cover HYPR?

1 analysts have issued ratings for Hyperfine, Inc. in the past 12 months.

Is HYPR a buy or sell right now?

Based on 1 analyst ratings, HYPR has a consensus rating of Buy (2.00/5) with a -13.0% upside to the consensus target of $1.60.

What are the earnings estimates for HYPR?

Analysts estimate HYPR will report EPS of $-0.34 for the period ending 2026-12-31, with revenue estimated at $20M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.